Caspase-1 Is Not Required for Type 1 Diabetes in the NOD Mouse
- William H. Schott1,
- Bradford D. Haskell1,
- Hubert M. Tse2,
- Martha J. Milton2,
- Jon D. Piganelli2,
- Caroline Morgane Choisy-Rossi1,
- Peter C. Reifsnyder1,
- Alexander V. Chervonsky1 and
- Edward H. Leiter1
- 1The Jackson Laboratory, Bar Harbor, Maine
- 2Department of Pediatrics, Division of Immunogenetics, Diabetes Institute, University of Pittsburgh, School of Medicine, Rangos Research Center, Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania
- Address correspondence and reprint requests to Edward Leiter, PhD, The Jackson Laboratory, Bar Harbor, ME 04609. E-mail: ehl{at}jax.org
Abstract
Interleukin (IL)-1β and IL-18 are two cytokines associated with the immunopathogenesis of diabetes in NOD mice. Both of these cytokines are cleaved by caspase-1 to their biologically active forms. IL-1 is a proinflammatory cytokine linked to β-cell damage, and IL-18 stimulates production of interferon (IFN)γ in synergy with IL-12. To examine the effects produced by caspase-1 deficiency on diabetes development in NOD/Lt mice, a disrupted Casp1 gene was introduced by a speed congenic technique. Casp1−/− bone marrow-derived macrophages stimulated with lipopolysaccharide produced no detectable IL-18, fourfold lower IL-1β, and 20–30% less IL-1α than macrophages from wild-type Casp1+/+ or Casp1+/− controls. Unexpectedly, despite reduced IL-1 and IL-18, there was no change in the rate of diabetes or in total incidence as compared with that in wild-type NOD mice. IL-1 reportedly makes an important pathological contribution in the multidose streptozotocin model of diabetes; however, there was no difference in sensitivity to streptozotocin between NOD mice and NOD.Casp1−/− mice at 40 mg/kg body wt or at 25 mg/kg body wt dosage levels. These findings show that caspase-1 processing of IL-1β and IL-18 is not absolutely required for mediation of spontaneous or chemically induced diabetes pathogenesis in the NOD mouse.
- CFA, complete Freund’s adjuvant
- ELISA, enzyme-linked immunosorbent assay
- IFN, interferon
- IL, interleukin
- LPS, lipopolysaccharide
- MLDSTZ, multiple low-dose streptozotocin
- STZ, streptozotocin
- TNF, tumor necrosis factor
Footnotes
-
- Accepted September 30, 2003.
- Received July 22, 2003.
- DIABETES














